Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2021-06-11 12:19:37
Oslo, Norway, 11 June 2021 - Reference is made to the stock exchange
announcement by Lytix Biopharma AS (the "Company") on 7 June 2021, regarding the
"private placement" and "national placement".
The Company has issued in total 12,234,116 new shares in said placements. The
share capital increases have now been registered with the Norwegian Register of
Business Enterprises (Nw.: Foretaksregisteret). The new registered share capital
of the Company is NOK 3,873,901.30, divided into 38,739,013 shares, each with a
nominal value of NOK 0.10.
For further information please contact:
Gjest Breistein (CFO), telephone: +47 952 60 512, e-mail:
Gjest.Breistein@lytixbiopharma.com
Lytix in brief: Based in Oslo, Norway, Lytix Biopharma is a clinical stage
biotech company developing novel cancer immunotherapies, an area within cancer
therapy that is aimed at activating the patient's immune system to fight cancer.
The Company's technology is based on pioneering research in "host defense
peptides" - nature's first line of defense towards foreign pathogens. Lytix
Biopharma's lead product, LTX-315, is a first-in-class oncolytic peptide with
the potential to personalize immunotherapy.